Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1320383,
author = {Pesek, Milos and Kolek, Vitezslav and Skřičková, Jana and Cernovska, Marketa and Koubkova, Leona and Roubec, Jaromir and Salajka, Frantisek and Zemanova, Milada and Krejci, Jana and Hejduk, Karel and Ryska, Ales and Minarik, Marek and Fiala, Ondrej},
booktitle = {16th World Conference on Lung Cancer},
keywords = {EGFR; NSCLC; EGFR-TKI; mutation},
language = {eng},
title = {Rare and Common EGFR Mutations in Patients with Advanced NSCLC Treated with EGFR-TKIs: A Registry-Based Study},
year = {2015}
}
TY - CONF
ID - 1320383
AU - Pesek, Milos - Kolek, Vitezslav - Skřičková, Jana - Cernovska, Marketa - Koubkova, Leona - Roubec, Jaromir - Salajka, Frantisek - Zemanova, Milada - Krejci, Jana - Hejduk, Karel - Ryska, Ales - Minarik, Marek - Fiala, Ondrej
PY - 2015
TI - Rare and Common EGFR Mutations in Patients with Advanced NSCLC Treated with EGFR-TKIs: A Registry-Based Study
KW - EGFR
KW - NSCLC
KW - EGFR-TKI
KW - mutation
N2 - Background: Erlotinib, gefitinib and afatinib, tyrosine kinase inhibitors directed at EGFR signalling (EGFR-TKI), are currently used for the treatment of patients with advancedstage non-small cell lung cancer (NSCLC). A considerable progress in the field of molecular oncology and cancer genomics in recent years has let to identification of several gene alterations predicting clinical outcome of patients treated with EGFR-TKIs. Activating EGFR mutations are widely recognized predictors of good response to EGFR-TKI treatment. While the predictive role of common EGFR mutations (exon 19 deletions and exon 21 L858R point mutation) is well described, very little clinical evidence data exist on the role of rare EGFR mutation types. The aim of this study was to assess the distribution of common and rare EGFR mutations in patients with NSCLC and to evaluate the efficacy of EGFR-TKIs for patients harboring rare and common EGFR mutations. Conclusion: While patients with frequent EGFR sensitive mutations have significant benefit from gefitinib therapy, patients with G719X mutation on exon 18 have marginal PFS and OS benefit, while pagtients with exon 20 insertion mutations have no demonstrable benefit from targeted therapy.Next generation tyrosinkinase inhibitors may prolong survival in some of rare EGFR mutated tumour patients.
ER -
PESEK, Milos, Vitezslav KOLEK, Jana SKŘIČKOVÁ, Marketa CERNOVSKA, Leona KOUBKOVA, Jaromir ROUBEC, Frantisek SALAJKA, Milada ZEMANOVA, Jana KREJCI, Karel HEJDUK, Ales RYSKA, Marek MINARIK a Ondrej FIALA. Rare and Common EGFR Mutations in Patients with Advanced NSCLC Treated with EGFR-TKIs: A Registry-Based Study. In \textit{16th World Conference on Lung Cancer}. 2015. ISSN~1556-0864.
|
